ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Goserelin

Also written as “Goserelin acetate”, “ZOLADEX” and “Inj. Goserelin (Test) Subcutaneously”.

Its studies are mostly in Breast Neoplasms · Prostatic Neoplasms · Metrorrhagia, led by 4 companies.

Drug pageGoserelin: every studyAll 103 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 26, 200512 company-led studies, 1 open or runningNext primary completion: Mar 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca80 open or runningphase 4since Oct 26, 2005Oct 10, 2005none ahead
Eurofarma Laboratoriosits history only20 open or runningphase 3since Apr 29, 2019Apr 29, 2019none ahead
Peptigroupeits history only10 open or runningphase 1since Jun 9, 2020Jun 9, 2020none ahead
TerSera Therapeuticsits history only11 open or runningphase 1since Dec 16, 2025Dec 16, 2025Mar 30, 2027phase 1 · NCT07310420

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 10, 2005First study: phase 2 study in Breast NeoplasmsFirst studyNCT00235937 · 45 enrolled · France
  2. Oct 26, 2005Phase 4 study in Prostatic NeoplasmsNCT00255268 · 15 enrolled · Mexico
  3. Mar 16, 2006Phase 2 study in Breast NeoplasmsNCT00303524 · 170 enrolled · Japan
  4. May 3, 2006Phase 2 study in NeoplasmsNCT00322348 · 98 enrolled · Czech Republic, Russian Federation, Ukraine
  5. Apr 23, 2009Phase 3 study in Breast NeoplasmsNCT00888082 · 102 enrolled · Turkey
  6. Feb 22, 2010Phase 3 study in Breast NeoplasmsNCT01073865 · 222 enrolled · India, Japan, Korea, Republic of and more
  7. Jun 27, 2018Phase 3 study in Breast NeoplasmsNCT03658213 · China
  8. Mar 21, 2019Phase 4 study in Advanced Prostate CancerNCT03971110 · 9 enrolled · China

TargetBeta

GNRH1 →GNRHR →read by rule
“A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
triptorelinruleIpsenphase 421

Studies

All 8 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03971110Advanced Prostate Cancer · China4TerminatedNov 9, 20229
NCT03658213Breast Neoplasms · China3WithdrawnNov 4, 20210
NCT01073865Breast Neoplasms · India, Japan, Korea, Republic of and more3CompletedSep 19, 2012222
NCT00888082Breast Neoplasms · Turkey3WithdrawnApr 2012102
NCT00322348Neoplasms · Czech Republic, Russian Federation, Ukraine2Completed98
NCT00303524Breast Neoplasms · Japan2CompletedAug 2007170
NCT00255268Prostatic Neoplasms · Mexico4Withdrawn15
NCT00235937Breast Neoplasms · France2Completed45

How it is read

Names in the registry

  • “Goserelin acetate”, 5 entries
  • “Goserelin”, 2 entries
  • “ZOLADEX”, 1 entry
  • “Inj. Goserelin (Test) Subcutaneously”, 1 entry
  • “Goserelin acetate 3.6 mg Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.